HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: M500243-MCP200v1 5/1/79    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Glossary Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pitarch, A. Articles by Gil, C. Search for Related Content PubMed PubMed Citation Articles by Pitarch, A. Articles by Gil, C. Social Bookmarking                      What's this?

Molecular & Cellular Proteomics 5:79-96, 2006.
© 2006 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Research

Decoding Serological Response to Candida Cell Wall Immunome into Novel Diagnostic, Prognostic, and Therapeutic Candidates for Systemic Candidiasis by Proteomic and Bioinformatic Analyses^*

Aida Pitarch, Antonio Jiménez, César Nombela^,¶ and Concha Gil^,||

From the Department of Microbiology II, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain and the Department of Internal Medicine II, Salamanca University Hospital, 37007 Salamanca, Spain

In an effort to bring novel diagnostic and prognostic biomarkers or even potential targets for vaccine design for systemic candidiasis (SC) into the open, a systematic proteomic approach coupled with bioinformatic analysis was used to decode the serological response to Candida wall immunome in SC patients. Serum levels of IgG antibodies against Candida wall-associated proteins (proteins secreted from protoplasts in active wall regeneration, separated by two-dimensional gel electrophoresis, and identified by mass spectrometry) were measured in 45 SC patients, 57 non-SC patients, and 61 healthy subjects by Western blotting. Two-way hierarchical clustering and principal component analysis of their serum anti-Candida wall antibody expression patterns discriminated SC patients from controls and highlighted the heterogeneity of their expression profiles. Multivariate logistic regression models demonstrated that high levels of antibodies against glucan 1,3-ß-glucosidase (Bgl2p) and the anti-wall phosphoglycerate kinase antibody seropositivity were the only independent predictors of SC. Receiver operating characteristic curve analysis revealed no difference between their combined evaluation and measurement of anti-Bgl2p antibodies alone. In a logistic regression model adjusted for known prognostic factors for mortality, SC patients with high anti-Bgl2p antibody levels or a positive anti-wall enolase antibody status, which correlated with each other, had a reduced 2-month risk of death. After controlling for each other, only the seropositivity for anti-wall enolase antibodies was an independent predictor of a lower risk of fatality, supporting that these mediated the protective effect. No association between serum anti-cytoplasmic enolase antibody levels and outcomes was established, suggesting a specific mechanism of enolase processing during wall biogenesis. We conclude that serum anti-Bgl2p antibodies are a novel accurate diagnostic biomarker for SC and that, at high levels, they may provide protection by modulating the anti-wall enolase antibody response. Furthermore serum anti-wall enolase antibodies are a new prognostic indicator for SC and confer protection against it. Bgl2p and wall-associated enolase could be valuable candidates for future vaccine development.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. W. J. de Groot, E. A. Kraneveld, Q. Y. Yin, H. L. Dekker, U. Gross, W. Crielaard, C. G. de Koster, O. Bader, F. M. Klis, and M. Weig The Cell Wall of the Human Pathogen Candida glabrata: Differential Incorporation of Novel Adhesin-Like Wall Proteins Eukaryot. Cell, November 1, 2008; 7(11): 1951 - 1964. [Abstract] [Full Text] [PDF]

				W. L. Chaffin Candida albicans Cell Wall Proteins Microbiol. Mol. Biol. Rev., September 1, 2008; 72(3): 495 - 544. [Abstract] [Full Text] [PDF]

				C. J. Clancy, M.-L. Nguyen, S. Cheng, H. Huang, G. Fan, R. A. Jaber, J. R. Wingard, C. Cline, and M. H. Nguyen Immunoglobulin G Responses to a Panel of Candida albicans Antigens as Accurate and Early Markers for the Presence of Systemic Candidiasis J. Clin. Microbiol., May 1, 2008; 46(5): 1647 - 1654. [Abstract] [Full Text] [PDF]

				A. Marcilla, J. E. De la Rubia, J. Sotillo, D. Bernal, C. Carmona, Z. Villavicencio, D. Acosta, J. Tort, F. J. Bornay, J. G. Esteban, et al. Leucine Aminopeptidase Is an Immunodominant Antigen of Fasciola hepatica Excretory and Secretory Products in Human Infections Clin. Vaccine Immunol., January 1, 2008; 15(1): 95 - 100. [Abstract] [Full Text] [PDF]

				M. L. Rodrigues, E. S. Nakayasu, D. L. Oliveira, L. Nimrichter, J. D. Nosanchuk, I. C. Almeida, and A. Casadevall Extracellular Vesicles Produced by Cryptococcus neoformans Contain Protein Components Associated with Virulence Eukaryot. Cell, January 1, 2008; 7(1): 58 - 67. [Abstract] [Full Text] [PDF]

				I. Pal-Bhowmick, M. Mehta, I. Coppens, S. Sharma, and G. K. Jarori Protective Properties and Surface Localization of Plasmodium falciparum Enolase Infect. Immun., November 1, 2007; 75(11): 5500 - 5508. [Abstract] [Full Text] [PDF]

				E. Fernandez-Arenas, V. Cabezon, C. Bermejo, J. Arroyo, C. Nombela, R. Diez-Orejas, and C. Gil Integrated Proteomics and Genomics Strategies Bring New Insight into Candida albicans Response upon Macrophage Interaction Mol. Cell. Proteomics, March 1, 2007; 6(3): 460 - 478. [Abstract] [Full Text] [PDF]